# EDGAR Filing Document

**Accession Number:** 0001860871
**File Stem:** 0001123292-25-000761
**Filing Date:** 2025-12
**Character Count:** 7178
**Document Hash:** 801d0ce37e922c652c664730d134fdfe
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001123292-25-000761.hdr.sgml**: 20251216

**ACCESSION NUMBER**: 0001123292-25-000761

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251216

**DATE AS OF CHANGE**: 20251216

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tevogen Bio Holdings Inc.
- **CENTRAL INDEX KEY:** 0001860871
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981597194
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93039
- **FILM NUMBER:** 251577010

**BUSINESS ADDRESS:**
- **STREET 1:** 15 INDEPENDENCE BOULEVARD, SUITE #210
- **CITY:** WARREN
- **STATE:** NJ
- **ZIP:** 07059
- **BUSINESS PHONE:** 646-807-8832

**MAIL ADDRESS:**
- **STREET 1:** 15 INDEPENDENCE BOULEVARD, SUITE #210
- **CITY:** WARREN
- **STATE:** NJ
- **ZIP:** 07059

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Semper Paratus Acquisition Corp
- **DATE OF NAME CHANGE:** 20210505
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Saadi Ryan H.
- **CENTRAL INDEX KEY:** 0002011728

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** C/O TEVOGEN BIO HOLDINGS INC.
- **STREET 2:** 15 INDEPENDENCE BLVD, SUITE 210
- **CITY:** WARREN
- **STATE:** NJ
- **ZIP:** 07059

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Tevogen Bio Holdings Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**88165K101**

*(CUSIP Number)*

**Ryan Saadi**<br>c/o Tevogen Bio Holdings Inc.<br>15 Independence Boulevard, Suite #210<br>Warren NJ 07059<br>877-838-6436

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/11/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **88165K101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ryan H. Saadi** | Name of reporting person<br>**Ryan H. Saadi** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**124334453.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**193923.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**96985499.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**193923.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**124528376.00** | Aggregate amount beneficially owned by each reporting person<br>**124528376.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**62%** | Percent of class represented by amount in Row (11)<br>**62%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The number of shares reported in row 7 includes 27,348,954 shares of restricted Common Stock that are outstanding and therefore carry voting rights but that may not be sold, assigned, transferred, pledged, hypothecated, or otherwise encumbered, subject to forfeit. The shares of Common Stock reported in rows 8 and 10 consist of shares held by Dr. Saadi's spouse. The percent reported in row 13 is calculated based on 201,011,792 shares of Common Stock outstanding as of December 16, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
Tevogen Bio Holdings Inc.

**(c) Address of Issuer's Principal Executive Offices:**
15 Independence Boulevard, Suite #210, Warren, NJ, 07059

This Amendment No. 2 to Schedule 13D (this "Amendment No. 2") relates to the common stock, par value $0.0001 per share (the "Common Stock"), of Tevogen Bio Holdings Inc., a Delaware corporation (the "Issuer" or the "Company"). This Amendment No. 2 amends and supplements the initial statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") by the Reporting Person on February 22, 2024, as amended by Amendment No. 1 to Schedule 13D filed with the SEC by the Reporting Person on July 25, 2025 (the "Original Schedule 13D," and as further amended by this Amendment No. 2, the "Schedule 13D"). Capitalized terms used but not defined in this Amendment No. 2 shall have the same meanings ascribed to them in the Original Schedule 13D. Except as otherwise provided herein, each Item of the Schedule 13D remains unchanged.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) of the Schedule 13D is hereby amended and restated to read as follows:

(a) See rows (11) and (13) of the cover page to this Amendment No. 2 for the aggregate number of shares of Common Stock and percentage of the shares of Common Stock beneficially owned by the Reporting Person.

**(b)**
Item 5(b) of the Schedule 13D is hereby amended and restated to read as follows:

(b) See rows (7) through (10) of the cover page to this Amendment No. 2 for the aggregate number of shares of Common Stock as to which the Reporting Person has the sole or shared power to vote or direct the vote and the sole or shared power to dispose or to direct the disposition.

**(c)**
Item 5(c) of the Schedule 13D is hereby amended and restated to read as follows:

(c) Except as set forth in this Amendment No. 2, the Reporting Person has not effected any transactions in the Common Stock in the 60 days prior to the date of this Amendment No. 2.

On December 11, 2025, the Reporting Person made gifts of an aggregate of 460,000 shares of Common Stock to charitable entities.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ryan H. Saadi

**Signature:** /s/ Ryan H. Saadi

**Name/Title:** Ryan H. Saadi

**Date:** 12/16/2025